Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COVENANT: HPV Vaccination to Reduce Cervical Lesions in HIV-Infected Women
NCT03284866Phase 3Completed
- Sponsor
- AIDS Malignancy Consortium
- Start
- Jul 2019
- Primary completion
- Nov 2024
- Modality
- Recombinant Protein Vaccines
- Countries
- 5
01
Overview
A Phase 3 trial of recombinant human papillomavirus 9-valent vaccine in Cervical Squamous Intraepithelial Lesion (SIL), Cervical Cancer (CC), sponsored by AIDS Malignancy Consortium. Started Jul 2019; status: completed.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
Cervical Squamous Intraepithelial Lesion (SIL)Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT03284866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03284866.